Drug Profile


Alternative Names: Gelsolin recombinant; hu r-P gelsolin; pGSN; Recombinant human plasma gelsolin; rh gelsolin; Solinex

Latest Information Update: 14 Jun 2016

Price : $50

At a glance

  • Originator Brigham and Womens Hospital
  • Developer BioAegis Therapeutics; Critical Biologics Corporation
  • Class Antineoplastics; Expectorants; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Community-acquired pneumonia
  • Discontinued Bronchitis; Cystic fibrosis; Systemic inflammatory response syndrome

Most Recent Events

  • 09 Jun 2016 Phase-I/II clinical trials in Community-acquired pneumonia in USA (Parenteral)
  • 20 May 2015 BioAegis plans a phase II trial in Pneumonia in Europe
  • 15 Apr 2015 BioAegis and the National Institute of Allergy and Infectious Disease enters into a collaborative research agreement for exploring the role of gelsolin in ameliorating effects of inflammation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top